Sol-Gel Technologies Ltd (SLGL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sol-Gel Technologies Ltd (SLGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8024
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sol-Gel Technologies Ltd (Sol-Gel) is a clinical-stage dermatology company that identifies, develops and commercializes branded and generic topical dermatological drug products for the treatment of skin diseases. The company’s pipeline products include vered, twin and sirs-t drug candidates. Its twin drug candidate is a non-antibiotic topical cream developed for the treatment of acne vulgaris or acne. Sol-Gel’s vered drug candidate is a topical encapsulated benzoyl peroxide cream developed for the treatment of papulopustular rosacea. The company’s sirs-t drug candidate is topical encapsulated tretinoin cream developed for the potential treatment of acne. It also develops silica-based microencapsulation technology platform. Sol-Gel is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd (SLGL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 11
Sol-Gel Technologies Enters into Agreement with CMO 12
Sol-Gel Technologies Amended Development Agreement with Perrigo 13
Licensing Agreements 14
Douglas Pharma Enters into Licensing Agreement with Sol-Gel Technologies 14
Sol-Gel Technologies Enters Into Licensing Agreement With US-Based Pharma Company For Dermatologic Drug 15
Equity Offering 16
Sol-Gel Tech Raises USD86.3 Million in IPO of Shares 16
Acquisition 18
Mori Arkin Plans to Acquire Sol-Gel for USD10 Million 18
Sol-Gel Technologies Ltd – Key Competitors 19
Sol-Gel Technologies Ltd – Key Employees 20
Sol-Gel Technologies Ltd – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
May 15, 2018: Sol-Gel Technologies Announces First Quarter 2018 Financial Results 22
Mar 26, 2018: Sol-Gel Technologies Reports Fourth Quarter and Full Year 2017 Financial Results 23
Corporate Communications 25
Sep 13, 2018: Sol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors 25
Clinical Trials 26
Feb 15, 2018: Sol-Gel presents Phase 2 Data on VERED at the 2018 American Academy of Dermatology Annual Meeting 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sol-Gel Technologies Enters into Agreement with Perrigo Israel Pharma 11
Sol-Gel Technologies Enters into Agreement with CMO 12
Sol-Gel Technologies Amended Development Agreement with Perrigo 13
Douglas Pharma Enters into Licensing Agreement with Sol-Gel Technologies 14
Sol-Gel Technologies Enters Into Licensing Agreement With US-Based Pharma Company For Dermatologic Drug 15
Sol-Gel Tech Raises USD86.3 Million in IPO of Shares 16
Mori Arkin Plans to Acquire Sol-Gel for USD10 Million 18
Sol-Gel Technologies Ltd, Key Competitors 19
Sol-Gel Technologies Ltd, Key Employees 20

List of Figures
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sol-Gel Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sol-Gel Technologies Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sol-Gel Technologies Ltd (SLGL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ono Pharmaceutical Co Ltd (4528)-医療機器分野:企業M&A・提携分析
    Summary Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a research-based pharmaceutical company, which carries out the discovery, production and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of diseases such as type I …
  • Kirin Holdings Co Ltd:戦略・SWOT・企業財務分析
    Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Kirin Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • GraIncorp Ltd (GNC):企業の財務・戦略的SWOT分析
    Summary GraIncorp Ltd (GrainCorp) is a grain supply company that provides storage services. The company offers services such as storage, marketing, handling, and logistics services to the grain growing industry. It also provides services such as research and development and commercialization; seed b …
  • United Overseas Bank Ltd:戦略・SWOT・企業財務分析
    United Overseas Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary United Overseas Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NovoCure Ltd (NVCR):医療機器:M&Aディール及び事業提携情報
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …
  • Sidi Kerir Petrochemicals Co (SKPC):企業の財務・戦略的SWOT分析
    Summary Sidi Kerir Petrochemicals Co (Sidpec), a subsidiary of Egyptian Petrochemicals Holding Co, is a chemical company that manufactures and distributes petrochemical products. The company offers high density polyethylene and linear low density polyethylene which are used in plastic applications i …
  • Entasis Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …
  • ClearOne Inc (CLRO):企業の財務・戦略的SWOT分析
    Summary ClearOne Inc (ClearOne) formerly ClearOne Communications Inc, is a technology company that provides conferencing, collaboration, streaming, and digital signage solutions. The company provides professional conferencing, audio and video distribution, premium conferencing, tabletop conferencing …
  • vTv Therapeutics Inc (VTVT)-製薬・医療分野:企業M&A・提携分析
    Summary vTv Therapeutics Inc (vTv), formerly TransTech Inc is a clinical stage pharmaceutical company that discovers, develops and commercializes small molecule drug candidates. The company’s pipeline products include azeliragon, TTP399, TTP273, HPP593, HPP737, HPP971 and hexokinase II inhibitors. I …
  • Barratt Developments Plc:企業の戦略・SWOT・財務情報
    Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report Summary Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Lukoil Oil Co (LKOH):企業の財務・戦略的SWOT分析
    Lukoil Oil Co (LKOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mitsubishi Heavy Industries Ltd (7011):電力:M&Aディール及び事業提携情報
    Summary Mitsubishi Heavy Industries Ltd (MHI) is a manufacturer of heavy machinery. It offers a diverse range of products and services for power plants, chemical plants, environmental equipment, steel structures, industrial and general machinery, shipbuilding, aircraft, space systems and air-conditi …
  • Suzuki Motor Corporation (7269):企業の財務・戦略的SWOT分析
    Suzuki Motor Corporation (7269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Electricity Generating Authority of Thailand:企業の戦略・SWOT・財務分析
    Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report Summary Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • JX Nippon Oil & Energy Corporation-エネルギー分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Stagecoach Group plc:企業の戦略・SWOT・財務情報
    Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report Summary Stagecoach Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mahindra Holidays & Resorts India Limited
    Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • OSE Immunotherapeutics (OSE):企業の財務・戦略的SWOT分析
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA, is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Heptares Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Heptares Therapeutics Ltd (Heptares), a subsidiary of Sosei Group Corp is a drug discovery company that develops small-molecule drugs. The company develops drugs for targeting G-protein-coupled receptors by utilizing its drug discovery technology platforms. Its technology platforms comprise …
  • Theranyx Sarl:製薬・医療:M&Aディール及び事業提携情報
    Summary Theranyx Sarl is a bio technology company that develops novel therapeutic drugs and solutions to treat cancer. The company’s main line business involved in generation of functional antibodies to target GPCRs and ion channel receptors. Its antibodies named as Therabodies has scope in target v …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆